Missed Doses

Some information presented within this Center of Excellence was created in collaboration with the California Department of State Hospitals (DSH). This includes that the content has been specifically aligned to the DSH’s medication guidelines (DSH Psychotropic Medication Operational Procedures, appended to DSH Policy Directive 3400). These medication guidelines are applicable only to the DSH settings and inclusion within this resource does not indicate that they must be followed in any non-DSH settings. The medication guidelines included in this resource are those of DSH and do not necessarily represent the views, policy(ies), and/or position(s) of the American Psychiatric Association (APA).

Please refer to the appropriate section of the FDA label as listed below for each medication. The label can be found by searching Drugs@FDA at the FDA website. Information is also available using the Drugs@FDA smartphone app.

• Abilify Maintena (aripiprazole monohydrate LAI) – Refer to label section 2.2: Dosage Adjustments for Missed Doses
• Aristada (aripiprazole lauroxil LAI) – Refer to label section 2.2: Missed Doses
• Invega Hafyera (paliperidone palmitate 6-mo LAI) – Refer to FDA label section 2.3: Missed Doses
• Invega Sustenna (paliperidone palmitate LAI) – Refer to label section 2.3: Missed Doses
• Invega Trinza (paliperidone palmitate 3-mo LAI) – Refer to label section 2.3: Missed Doses
• Risperdal Consta (risperidone LAI) – Refer to FDA label section 2.1: Schizophrenia/Reinitiation
• Uzedy (risperidone for extended-release solution) – Refer to label section 2.1: Recommended Dosage
• Erzofri (paliperidone palmitate LAI) – Refer to label section 2.2 (https://erzofrihcp.com/wp-content/uploads/erzofri_prescribing_information_3.25.pdf):  Missed Doses

There is no specific guidance from the FDA on how to handle missed doses of the following LAIs:

• Haldol decanoate (haloperidol LAI)
• Prolixin decanoate (fluphenazine LAI)